References
- Maeshima AM, Taniguchi H, Tanioka K, et al. Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement. Leuk Lymphoma 2015;56:2000–2004.
- Solal-Celigny P, Roy P, Colombar P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1256–1265.
- Spiro S, Galton DA, Wiltshaw E. et al. A survey of 75 cases with special reference to the syndrome resembling chronic lymphocytic leukemia. Br J Cancer 1975;31:60–72.
- Melo JV, Robinson DSF, De Oliveira MP, et al. Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma. J Clin Pathol 1988;41:951–959.
- Chubachi A, Miura J, Hashimoto K, et al. High incidence of leukemic phase in follicular lymphoma in Akita, Japan: clinicopathologic, immunological and cytogenetic studies. Eur J Haematol 1993;50: 103–109.
- Bain BJ, Catovsky D. The leukaemic phase of non-Hodgkin's lymphoma. J Clin Pathol 1995;48:189–193.
- Al-Nawakil C, Kosmider O, Stern MH, et al. Leukemic phase of follicular lymphomas: an atypical presentation. Leuk Lymphoma 2011;52:1504–1508.
- Beltran BE, Castillo JJ, Quiñones P, et al. Follicular lymphoma in leukemic phase at diagnosis. Report of seven cases and review of the literature. Leuk Res 2011;37:1116–1119.
- Inaba T, Okamoto A, Tatsumi T, et al. Hyperleukocytosis in patients with leukemic follicular lymphoma. Ann Haematol 2007;86:299–300.
- Paszkiewicz-Kozik E, Kulik J, Fabisiewicz A, et al. Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma. Med Oncol 2009;26:16–21.
- Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol 2014;32:1347–1355.
- Sarkozy C, Basseggio L, Feugier P, et al. Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. Br J Haematol 2014;164:659–667.
- Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cycloposphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579–4586.
- Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cycophosphamide, doxorubicin, vincritine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the german Low-Grade Lymphoma Study Group. Blood 2005;106:3725–3732.
- Kodaira M, Takeuchi K, Nara E, et al. Leukemic presentation is a predictive indicator for relapse for patients with follicular lymphoma treated with rituximab containing initial therapy. Blood 2009;114(Suppl. 1): Abstract 4763.
- Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 randomized controlled trial. Lancet 2011;377:42–51.
- Salles G, Seymour JF, Feugier P, et al .Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy. Blood 2013;122(Suppl. 1): Abstract 509.
- Sarkozy C, Seymour JF, Ferme C, et al. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood 2014;123:2740–2742.
- Ghielmini M, Vitolo U, Kimby E, et al.;Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24: 561–576.